Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Enterprise Value: 2020-2025

Historic Enterprise Value for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$90.0 million.

  • SAB Biotherapeutics' Enterprise Value fell 1532.44% to -$90.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.3 million, marking a year-over-year increase of 9.88%. This contributed to the annual value of $14.3 million for FY2024, which is 169.22% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Enterprise Value of -$90.0 million as of Q3 2025, which was down 949.16% from $10.6 million recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' Enterprise Value peaked at $431.7 million during Q3 2021, and registered a low of -$90.0 million during Q3 2025.
  • Its 3-year average for Enterprise Value is -$2.9 million, with a median of -$217,506 in 2025.
  • Data for SAB Biotherapeutics' Enterprise Value shows a peak YoY increase of 221.55% (in 2025) and a maximum YoY decrease of 1,532.44% (in 2025) over the last 5 years.
  • SAB Biotherapeutics' Enterprise Value (Quarterly) stood at $300.0 million in 2021, then plummeted by 96.55% to $10.3 million in 2022, then plummeted by 299.25% to -$20.6 million in 2023, then surged by 169.22% to $14.3 million in 2024, then tumbled by 1,532.44% to -$90.0 million in 2025.
  • Its Enterprise Value was -$90.0 million in Q3 2025, compared to $10.6 million in Q2 2025 and -$217,506 in Q1 2025.